Clinical features and prognosis of primary intestinal B-cell lymphoma: analyses of 50 cases
10.3760/cma.j.issn.1009-9921.2018.09.004
- VernacularTitle:原发性肠道B细胞淋巴瘤50例临床特征及预后分析
- Author:
Lili PAN
1
;
Jie PAN
;
Lihong CHEN
;
Xiaoyun ZHENG
;
Zhihong ZHENG
;
Jianda HU
;
Tingbo LIU
Author Information
1. 福建省血液病研究所 福建省血液病学重点实验室 福建医科大学附属协和医院血液科
- Keywords:
Lymphoma,B-cell;
Intestinal neoplasms;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2018;27(9):525-528,532
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics and prognostic factors for patients with primary intestinal B-cell lymphoma. Methods The clinical data of 50 patients with primary intestinal B-cell lymphoma in Fujian Medical University Union Hospital from January 2004 to December 2013 were retrospectively analyzed. An analysis was also conducted in their clinical characteristics and related prognostic factors. Results A total of 50 patients included 35 males and 15 females with the median age of 58 years old (16-79 years old). The clinical symptoms were abdominal pain or abdominal distension [70 % (35/50)]. The common origins were small intestine and ileocecus, and the most common pathological type was diffuse large B-cell lymphoma (DLBCL) [54 % (27/50)]. The median survival time of 43 cases was 49.4 months. The 1-year, 3-year and 5-year overall survival (OS) rates were 79.1 %, 72.1 %, 58.1 %, respectively. Univariate analysis indicated that hemoglobin levels, albumin levels, lactic dehydrogenase (LDH), the maximum diameter of mass, international prognostic index (IPI) score, Lugano stage, and Eastern Cooperative Oncology Group (ECOG) score were the affecting factors of OS. Multivariate analysis showed that IPI score ≥ 2 was an independent risk factor for the prognosis of intestinal B-cell lymphoma ( OR＝ 6.766, 95 % CI 1.853-24.702, P＝ 0.004). The efficacy analysis showed that 5-year cumulative OS rate of R-CHOP like treatment group was better than that of CHOP like treatment group (91.7 % vs. 44.7 %, P ＝0.048). Conclusion IPI score can be used as an important indicator for clinical treatment and prognosis evaluation of primary intestinal B-cell lymphoma. Some patients with primary intestinal B-cell lymphoma can benefit from rituximab.
